Edition:
India

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

5.98USD
11:34pm IST
Change (% chg)

$-0.12 (-1.97%)
Prev Close
$6.10
Open
$6.10
Day's High
$6.49
Day's Low
$5.75
Volume
64,574
Avg. Vol
53,154
52-wk High
$21.30
52-wk Low
$3.13

Select another date:

Thu, Nov 2 2017

BRIEF-Catalyst biosciences Q3 loss per share $1.34

* Catalyst Biosciences reports third quarter 2017 operating & financial results and provides corporate update

BRIEF-Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration

* Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration to develop intravitreal anti-complement factor 3 (c3) products for the treatment of dry amd and other retinal diseases

BRIEF-Catalyst Biosciences Inc - ‍companies plan to have interim, top-line results by end of 2017

* Catalyst Biosciences granted FDA orphan drug designation for subcutaneous recombinant human Factor IX variant for treatment of hemophilia B

BRIEF-Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial

* Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial

BRIEF-Catalyst Biosciences Inc announces issuance of Asia patents covering Factor IX Hemophilia Program

* Catalyst Biosciences Inc - announces issuance of Asia patents covering factor IX Hemophilia Program Source text for Eikon: Further company coverage:

BRIEF-Catalyst Biosciences' reports positive data on hemophilia B drug

* Catalyst Biosciences announces positive factor ix clinical data

BRIEF-Catalyst Biosciences posts Q2 loss of $2.53 per share

* Catalyst biosciences reports second quarter 2017 financial results and provides subcutaneous (sq) hemophilia program update

BRIEF-Financial milestone achieved in Catalyst's subcutaneous factor IX program

* Financial milestone achieved in Catalyst's subcutaneous factor IX program

BRIEF-Catalyst Biosciences' Factor IX granted orphan drug designation in Europe

* Catalyst Biosciences' Factor IX granted orphan drug designation in Europe

BRIEF-Catalyst Biosciences announces achievement of stable normal factor IX blood levels in a preclinical subcutaneous dosing model

* Catalyst Biosciences announces achievement of stable normal factor IX blood levels in a preclinical subcutaneous dosing model Source text for Eikon: Further company coverage:

Select another date: